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Abstract
Introduction: The relationship between circulating prolactin and invasive breast cancer has been investigated
previously, but the association between prolactin levels and in situ breast cancer risk has received less attention.
Methods: We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer
overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional
logistic regression was used to assess this association in a case-control study nested within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched
control subjects.
Results: We found a significant positive association between higher circulating prolactin levels and risk of in situ
breast cancer among all women [pre-and postmenopausal combined, ORlog2 = 1.35 (95% CI 1.04-1.76), Ptrend = 0.03].
No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal
status (Phet = 0.98) or baseline HT use (Phet = 0.20), although the observed association was more pronounced among
postmenopausal women using HT compared to non-users (Ptrend = 0.06 vs Ptrend = 0.35). In subgroup analyses, the
observed positive association was strongest in women diagnosed with in situ breast tumors <4 years compared
to ≥4 years after blood donation (Ptrend = 0.01 vs Ptrend = 0.63; Phet = 0.04) and among nulliparous women compared
to parous women (Ptrend = 0.03 vs Ptrend = 0.15; Phet = 0.07).
Conclusions: Our data extends prior research linking prolactin and invasive breast cancer to the outcome of
in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ
breast cancer.
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Introduction
In situ breast tumours account for about 20% of all
breast cancers diagnosed by mammography [1] and ap-
proximately a third of invasive breast cancers are re-
ported to originate from breast carcinoma in situ [1-3],
which may be a precursor of invasive breast cancer [4].
The focus on in situ breast cancer, therefore, offers the
advantage of exploring the associations with risk factors
that are important early in the carcinogenic process (that
is, prior to development of invasive disease) and early in
the natural history of breast cancer, increasing our un-
derstanding of the aetiology of breast cancer. Identifying
common versus distinct risk factors for in situ and inva-
sive disease will, in part, provide insight into the com-
mon versus distinct mechanisms through which these
cancers develop. Further, in situ breast cancers are rela-
tively aggressively treated with surgery, radiation and/or
hormone therapies [1], underscoring the importance of
identifying risk factors for this breast cancer subtype.
The relationship between circulating prolactin and in-
vasive breast cancer risk has been investigated previously
[5,6]. In our previous study we found a modest positive
association between circulating prolactin levels and
invasive breast cancer risk among postmenopausal
women (odds ratio (OR)Q4-Q1 = 1.29 (95% CI 1.05,1.58),
Ptrend = 0.09) [5].
The association between prolactin and in situ breast
cancer risk, however, has received less attention. In the
Nurses’ Health Study, the only large-scale prospective
study reporting estimates separately for women with
invasive and in situ lesions, the increased risk ap-
peared to be confined primarily to invasive cancers
(ORQ4-Q1 = 1.38 (95% CI 1.11, 1.73), Ptrend = 0.0005
for invasive versus ORQ4-Q1 = 1.16 (95% CI 0.77, 1.74),
Ptrend = 0.23 for in situ breast cancer among postmeno-
pausal women], although there was no heterogeneity
comparing in situ versus invasive cancer (P-value for het-
erogeneity (Phet) = 0.81) [6]. The only other study to date
that included subjects with in situ breast cancer did not
provide estimates separately by in situ versus invasive
disease [7].
Therefore, in this study we examined the association
between pre-diagnostic prolactin concentrations among
pre- and postmenopausal women with subsequent
risk of in situ breast cancer overall, by menopausal
status and by use of postmenopausal hormone ther-
apy (HT) at the time of blood donation within the
European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort.
Methods
The EPIC cohort
The EPIC cohort is based on 366,521 women and
153,457 men recruited between the years 1992 and 2000
in 10 European countries: Denmark, France, Germany,
Greece, Italy, Norway, Spain, Sweden, The Netherlands,
and the United Kingdom. Details on the subject recruit-
ment, baseline data and blood collection protocols have
been reported previously [8]. All EPIC study participants
provided written consent for the use of questionnaire in-
formation and blood samples in research studies. Ethical
approval for the EPIC study was obtained from the eth-
ical review boards of the International Agency for
Research on Cancer (IARC) (Lyon, France) and from the
local ethics committees in participating countries/study
centres (the names of all local ethics committees that ap-
proved the study are available Acknowledgements). The
current study was additionally approved by the ethical
review board at IARC (which holds the central bioreposi-
tory for EPIC) and the ethical review board in Heidelberg
(Heidelberg University), where the laboratory assays and
statistical analyses were performed.
Details on vital-status follow up and ascertainment of
breast cancer incidence across the study centres were re-
ported previously [9]. Briefly, in all countries (except for
France, Greece, and Germany) incident breast cancer
cases were identified using a combination of methods
employing record linkage with cancer and pathology
registries. In Greece, Germany, and France, active follow
up of cancer was through health insurance records and
direct contact with participants. Self-reported breast
cancer cases were all systematically verified from clinical
and pathologic records. Breast cancer in situ inci-
dence data were coded according to the International
Classification of Disease (ICD-10 code D05). For the
present study, the closure date for follow up was the
last date of complete follow up for both cancer inci-
dence and vital status, which ranged from 2003 to
2006, depending on the study centre. Sweden was not in-
cluded in the analysis because independent studies were
being completed on breast cancer risk and endogenous
hormones [7].
Design of the nested case-control study
General criteria for the inclusion of cases and matched
controls into the study were: (1) women had an available
blood sample; (2) could be clearly classified as being ei-
ther premenopausal or postmenopausal at the time they
provided their blood sample, and (3) did not have any
previous diagnosis of cancer (except non-melanoma skin
cancer). For each case, one matched control (closest to
the case, based on matching criteria) with an available
blood sample was chosen using incidence density sam-
pling among appropriate risk sets consisting of all cohort
members who were alive and free of cancer at the time
of diagnosis of the index case. Matching criteria were:
study recruitment centre, menopausal status at blood
donation, age at blood donation (±6 months), time at
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blood donation (±2 h), fasting status, phase of menstrual
cycle (matching categories for premenopausal women:
early follicular (days 0 to 7 of the cycle), late follicular
(days 8 to 11), mid-cycle (days 12 to 16), early luteal
(days 17 to 19), mid luteal (days 20 to 24), late luteal
(days 25+), and current use of HT at the time of blood
donation (for postmenopausal women).
In total, 307 in situ breast cancer cases and an equal
number of control subjects were selected for the study. In
our analysis, the majority of the cases (91%) were defined
as ductal carcinoma in situ and 9% as lobular carcinoma in
situ or carcinoma in situ NOS (not otherwise specified).
Laboratory assays
Prolactin assays were performed in the laboratory of the
Division of Cancer Epidemiology at the German Cancer
Research Centre (DKFZ) and determined by immunora-
diometric assay (IRMA (CT), IBL International GMBH,
Germany) in blood collected at baseline. The case-
control pairs were analysed in the same batch and qual-
ity controls were included in each analytical batch.
Laboratory personnel were blinded to the case-control
status of samples and quality controls. The detection
range of the assay was 0.35 to 133 ng/mL. The mean
inter- and intra-assay coefficients of variation were
4.62% and 2.17%, respectively.
Statistical analyses
Conditional logistic regression was used to estimate ORs
and 95% CI for breast cancer in situ occurrence. ORs
were calculated across tertiles of circulating prolactin
and on a continuous log2 scale. Linear trends for OR es-
timates were calculated over a continuous log2 scale of
prolactin. Circulating prolactin levels vary by meno-
pausal status [10], and therefore the tertile cutpoints
were defined separately for pre- and postmenopausal
women, based on distributions in the control population.
We decided a priori to adjust all models for parity
(nulliparous, parous, or missing data), smoking status
(current, never, previous, missing data) and body mass
index (BMI) in kg/m2 (continuous scale), due to modest
variation in prolactin levels over these factors in healthy
women [10]. A more detailed description of the statis-
tical analysis (including other variables tested for
possible confounding) used in this study is described
previously [5]. Additionally, for the comparison of the
results from our present analysis on in situ breast cancer
and our prior results on invasive breast cancer [5], a
case-case analysis was performed [11]. All P-values pre-
sented are two-sided and P <0.05 was considered statisti-
cally significant. Statistical analyses were conducted
using SAS software, version 9.2 (SAS Institute, Cary,
NC, USA).
Results
This nested case-control study consisted of 307 cases di-
agnosed with in situ breast cancer, and an equal number
of controls. For the premenopausal case-control pairs,
the median age at blood donation was 46.4 years (range
34.1 to 56.4 years), and the median age at diagnosis for
the cases was 50.6 years (range 37.3 to 61.3) (Table 1).
Among postmenopausal women the ages at blood dona-
tion and diagnosis were 58.1 years (range 47.7 to 71.4)
and 62.8 years (range 51.0 to 78.3), respectively. The me-
dian follow-up time between blood donation and date of
diagnosis was 4.2 years (range 0.02 to 10.7 years). This
study included 82 postmenopausal case-control pairs
who used HT at the time they provided their baseline
blood sample. Out of 307 in situ cases selected to this
analysis, 15 patients developed invasive breast cancer
after diagnosis of in situ disease during further follow
up. The median levels of prolactin were 8.3 ng/mL
(range 3.8 to 28.1 ng/mL) for patients who developed
invasive disease after diagnosis of in situ disease and
Table 1 Baseline characteristics of in situ breast cancer case and control subjects (data presented as median [min, max]
or n [%])
Premenopausal women* Postmenopausal women*
Cases (n = 86) Controls (n = 86) Cases (n = 221) Controls (n = 221)
Age at blood donation, years 46.4 (34.1, 56.4) 46.5 (34.4, 55.6) 58.1 (47.7, 70.6) 58.0 (47.7, 71.4)
Age at menopause, years 50.0 (33.0, 59.0) 50.0(29.0,58.0)
Age at diagnosis, years 50.6 (37.3, 61.3) 62.8 (51.0, 78.3)
Lag time till diagnosis, years 4.1 (0.02, 10.0) 4.4 (0.02, 10.7)
Body mass index, kg/m2 23.3 (17.1, 32.8) 24.0 (17.4, 37.2) 24.9 (17.8, 40.8) 24.5 (18.2, 45.9)
Ever had a full-term pregnancy 68 (82.9) 70 (81.4) 190 (86.8) 188 (85.5)
Baseline smoking 15 (17.4) 20 (23.3) 25 (11.3) 33 (14.9)
Baseline use of hormone therapy 82 (37.1) 82 (37.1)
Prolactin levels, ng/mL 8.9 (3.4, 51.7) 7.7 (2.9, 133.0) 6.2 (2.6, 128.3) 5.9 (2.6, 55.3)
Data are presented as median (minimum, maximum) or number (%). *Menopausal status at the time of blood donation.
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6.8 ng/mL (range 2.6 to 128.3 ng/mL) in patients
who did not develop invasive disease during further
follow up (data not shown).
In conditional logistic regression analyses adjusting for
parity, smoking status, and BMI, there was a positive as-
sociation between prolactin concentrations and in situ
breast cancer risk among all women (pre-and postmeno-
pausal combined), with a statistically significant 35% in-
crease in risk for each one unit increase in prolactin on
the continuous log2 scale (ORlog2 = 1.35 (95% CI 1.04,
1.76), Ptrend = 0.03) (Table 2). The association was similar
comparing the top to the bottom tertiles of prolactin,
but did not reach statistical significance (ORQ3-Q1 = 1.37
(95% CI 0.87, 2.16)). We observed no statistically signifi-
cant heterogeneity in stratified analyses by menopausal
status (Phet = 0.98). However, after additional stratifica-
tion by baseline HT use among postmenopausal women,
we observed a suggestive association among the HT
users (ORlog2 = 1.77 (95% CI 0.98, 3.21), Ptrend = 0.06),
but not among the non-users (ORlog2 = 1.20 (95% CI
0.82, 1.76), Ptrend = 0.35). However, case numbers in
these subgroups were small, CIs overlapping and the test
for heterogeneity between HT users and non-users was
not statistically significant (Phet = 0.20).
In subgroup analyses (Table 3), we observed significant
heterogeneity in the strength of the association with
in situ breast cancer risk by time between blood do-
nation and diagnosis (that is, lag time) among all
women (Phet = 0.04). Higher concentrations of prolac-
tin were significantly associated with in situ breast
cancer diagnosed less than 4 years since blood donation
(ORlog2 = 1.78 (95% CI 1.12, 2.84), Ptrend = 0.01), but not
with breast cancer diagnosed 4 or more years since blood
donation (ORlog2 = 1.09 (95% CI 0.77, 1.55), Ptrend = 0.63;
Phet = 0.04). Similarly, the estimated association of pro-
lactin with in situ breast cancer risk appeared stronger
among nulliparous women compared to parous women,
more pronounced in analysis restricted to postmeno-
pausal women (ORlog2 = 5.10 (95% CI 1.23, 21.15),
Ptrend = 0.02 in nulliparous women versus ORlog2 = 1.22
(95% CI 0.88, 1.68), Ptrend = 0.24 in parous women;
Phet = 0.02). It should be noted, however, that the
case numbers for nulliparous women were small and
the CIs for risk estimates wide. There was no signifi-
cant heterogeneity by age at tumour diagnosis in either
premenopausal or postmenopausal women (Phet = 0.87)
(data not shown).
Additional statistical analyses showed no evidence
for major confounding effects by other lifestyle and
reproductive factors nor was there an interaction be-
tween prolactin and BMI (Pinteraction = 0.84) (data not
shown).
Finally, we compared the results from our present ana-
lysis on in situ breast cancer and from our prior analysis
on invasive breast cancer [5]. The median levels of
prolactin comparing in situ (n = 307) versus invasive
Table 2 Adjusted odd ratiosa (OR) for in situ breast cancer by tertile levels and on a continuous log2 scale of
circulating prolactin
Tertiles Log2
1 2 3 Odds ratio (95% CI) Ptrend
b Phet
c
All women
Ca/Co 89/101 94/104 124/102
OR Ref. 0.98 (0.65, 1.49) 1.37 (0.87, 2.16) 1.35 (1.04, 1.76) 0.03
Premenopausal
Ca/Co 27/29 19/28 40/29
OR Ref. 0.63 (0.25, 1.58) 1.49 (0.59, 3.74) 1.30 (0.80, 2.10) 0.28
Postmenopausal (all)
Ca/Co 65/72 69/75 87/74 0.98
OR Ref. 1.00 (0.61, 1.63) 1.31 (0.77, 2.22) 1.38 (1.00, 1.91) 0.05
Postmenopausal non-HT users
Ca/Co 50/51 39/49 50/39
OR Ref. 0.84 (0.44, 1.6) 1.27 (0.65, 2.47) 1.20 (0.82, 1.76) 0.35
Postmenopausal HT users
Ca/Co 15/21 30/26 37/35 0.20
OR Ref. 1.63 (0.70, 3.81) 1.62 (0.64, 4.09) 1.77 (0.98, 3.21) 0.06
aAdjusted for parity (nulliparous, parous, or missing data), smoking status (current, never, previous, or missing data) and body mass index (continuous scale);
blinear trends for odds ratio estimates over a continuous scale of prolactin levels; cstatistical tests for heterogeneity were based on the likelihood-ratio test,
comparing the model fit for logistic regression models with and without a corresponding interaction term. Ca/Co, Case/Control; Ref., reference; HT, hormone therapy.
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breast cancer tumors (n = 2250) were 8.9 (in situ) versus
8.6 ng/mL (invasive) for premenopausal women and 6.2
(in situ) versus 6.1 (invasive) ng/mL for the postmeno-
pausal women (data not shown). A heterogeneity test
comparing in situ versus invasive disease was not statisti-
cally significant (Phet = 0.25 for premenopausal women
and Phet = 0.33 for postmenopausal women).
Discussion
In this prospective study, we observed a significant posi-
tive association between pre-diagnostic circulating pro-
lactin levels and risk of in situ breast cancer. Our data
showed no evidence for heterogeneity in the relationship
of prolactin levels and in situ cancer risk by menopausal
status or postmenopausal HT use at blood donation,
although the observed positive association was more
pronounced among HT users versus non-users. In
addition, the associations were strongest among women
diagnosed with in situ breast tumors less than 4 years
after blood donation and also among nulliparous
women.
Our findings of modest, positive associations between
prolactin and in situ breast cancer risk are similar to
those observed for invasive breast cancer. Prior analyses
limited to invasive cases found modest significant associ-
ations between circulating prolactin and risk of invasive
breast cancer, with up to a 50% increase in risk contrast-
ing top versus bottom quartiles [5,6]. Moreover, compar-
able to our previous findings for invasive breast cancer
[5], the observed association in the present study of
in situ breast cancer was more pronounced among post-
menopausal HT users as compared to non-users. Al-
though in situ carcinomas in the breast may not have
invasive characteristics [12], up to 50% of in situ lesions,
if left untreated, progress to invasive disease [3]. Little is
known about the exact mechanisms influencing the pos-
sible progression of in situ lesions to invasive disease.
However, the very similar associations between prolactin
and breast cancer risk observed in our previous study of
invasive disease [5] and the current study of in situ dis-
ease suggest that circulating prolactin may influence risk
of invasive and in situ breast cancer via the same
aetiological pathway. Prolactin may also play a role in
progression from in situ to invasive breast cancer. How-
ever, out of 307 in situ cases selected for this analysis,
only 15 developed invasive breast cancer during further
follow up. Therefore, we were unable to assess the asso-
ciation between prolactin and progression from in situ
to invasive disease in this study.
Although a vast body of evidence from animal,
in vitro, and epidemiological studies strongly supports
the involvement of prolactin in breast cancer develop-
ment [5,6,13,14], the complex and diverse biological and
molecular mechanisms through which prolactin may in-
crease risk of breast cancer are not clear. Some proposed
mechanisms include its proliferative effects on malignant
breast cells, mitogenic action, and inhibition of apoptosis
via signalling through the prolactin receptor [14]. In
addition to the endocrine (circulating) concentrations,
locally produced prolactin may promote cancer de-
velopment via autocrine and paracrine effects [15].
Evidence is also emerging that drugs resulting in
Table 3 Adjusted odds ratiosa (OR) for in situ breast
cancer on a continuous log2 scale of circulating prolactin
by subgroup analysis
Case-control
sets, number
Log2 odds
ratio (95% CI)
Ptrend
b Phet
c
All women
Lag time till diagnosis
<4 years 127 1.78 (1.12, 2.84) 0.01 0.04
≥4 years 180 1.09 (0.77, 1.55) 0.63
Parityd
Nulliparous 42/45 2.64 (1.07, 6.51) 0.03 0.07
Parous 251/251 1.21 (0.94, 1.57) 0.15
Premenopausal women
Lag time till diagnosis
<4 years 39 2.30 (0.85, 6.14) 0.10 0.15
≥4 years 47 0.97 (0.51, 1.83) 0.92
Postmenopausal women
(all)
Lag time till diagnosis
<4 years 88 1.66 (0.97, 2.85) 0.07 0.19
≥4 years 133 1.18 (0.76, 1.82) 0.46
Parityd
Nulliparous 29/32 5.10 (1.23,
21.15)
0.02 0.02
Parous 187/185 1.22 (0.88, 1.68) 0.24
Postmenopausal non-HT
users
Lag time till diagnosis
<4 years 52 1.20 (0.70, 2.05) 0.51 0.52
≥4 years 87 1.08 (0.61, 1.93) 0.79
Postmenopausal
HT users
Lag time till diagnosis
<4 years 36 6.02 (1.31,
27.72)
0.02 0.04
≥4 years 46 1.29 (0.64, 2.61) 0.47
aAdjusted for parity (nulliparous, parous, missing data), smoking status
(current, never, previous, or missing data) and body mass index (continuous
scale); blinear trends for odds ratio estimates over a continuous scale of
prolactin levels; cheterogeneity between subgroups was based on the chi-square
test; dusing unconditional logistic regression, adjusted for age and time at blood
donation, fasting and smoking status, body mass index, phase of menstrual cycle
for premenopausal women and current use of hormone therapy (HT) for
postmenopausal women.
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elevated prolactin (for example, neuroleptic and hormonal
medications) may increase breast cancer risk [16,17].
The relationship between prolactin and in situ breast
cancer risk was confined to tumors diagnosed within the
first 4 years from blood donation. Interestingly, this dif-
ferential association by time between blood collection
and diagnosis was not evident for invasive breast cancer
risk in our previous analysis [5]. Whether prolactin is in-
volved in the early development or promotes late-stage
growth of an established tumor is unclear. Consistent
with the current analysis, recent results from the Nurses’
Health Study suggest that prolactin primarily plays a role
in the late stage of tumor development, with stronger
positive associations observed among participants pro-
viding blood samples closer to diagnosis [6,18]. This is
also supported by studies observing elevated levels of
circulating prolactin in breast cancer patients [19], and
demonstrating the ability of breast tumors to secrete
prolactin [13]. However, our present analysis suggests
that prolactin may also operate early in the natural his-
tory of breast cancer by increasing risk of in situ tumors,
the earliest detectable breast carcinomas.
In the current study, prolactin was associated with in
situ breast cancer among postmenopausal nulliparous
women but not in parous women. Parity, a well-
established protective factor for breast cancer [20], has
been associated with a long-term post-pregnancy reduc-
tion in levels of circulating prolactin [10,21]. Our results
support the hypothesis that lowered prolactin levels fol-
lowing pregnancy might serve as one of several possible
mechanisms that mediate the long-term reduction in
risk afforded by parity. However, our findings should be
interpreted with caution as only about 15% of women
in this case-control study were nulliparous and OR
estimates for nulliparous women had wide confidence
limits.
Our study is the second largest prospective study on
the association between prolactin and breast cancer risk,
to provide risk estimates for in situ breast cancer. A gen-
eral limitation of our study is that prolactin levels were
measured only at a single point in time. However, reli-
ability studies in which repeat blood samples were taken
over intervals of up to three years have shown relatively
high intra-class correlation (ICC coefficients of up
to 0.76) between individuals’ serum prolactin levels over
time [22-24]. In situ breast cancer is largely diagnosed as
a result of mammography; however, we were not able to
adjust our models for the participation in mammo-
graphic screening, nor were we able to compare rates of
screening in cases and controls. Our study had relatively
limited numbers of case subjects for subgroup analysis,
and thus the statistical power for detecting associations
of prolactin with risk in these subgroups was limited.
Due to very limited information available for the
molecular characteristics of in situ tumors, we were not
able to perform the analysis by molecular subtypes of
the lesions.
Conclusions
In conclusion, we have extended prior research showing
an association between prolactin and invasive breast
cancer to the outcome of in situ breast cancer. Our
study shows that higher circulating levels of prolactin
may be associated with increased risk of in situ breast
cancer. It is estimated that up to 50% of untreated in situ
breast lesions will progress to invasive disease. However,
we are currently not able to distinguish between indo-
lent and more aggressive in situ carcinomas, and the
side effects of the medical management of in situ lesions
(for example, lumpectomy, radiation and/or hormone
therapy) are not negligible. Therefore, identification of
risk factors for in situ breast carcinomas is important
both from the perspective of characterizing the risk of
the disease as diagnosed and treated, as well as providing
insight into the aetiology of the in situ carcinomas,
which represent pre-invasive disease. Additional work to
characterize circulating prolactin and risk of invasive
disease, particularly after the development of in situ
breast disease, is needed.
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